ImmVira, a pioneering biotechnology company, has unveiled groundbreaking data on its engineered exosome MVR-EX105 at the 2025 International Federation for the Surgery of Obesity and Metabolic Disorders Congress. The company’s lead candidate, EX105, utilizes a bio-derived nano-size delivery system developed on the OVPENS platform to target fat reduction and muscle preservation through the process of white adipose tissue browning. By arming the exosome’s surface with key functional proteins like FGF-21, IL-27, and the ActRIIB extracellular domain, EX105 triggers the conversion of energy-storing white adipose tissue into energy-burning brown adipose tissue. This metabolic shift not only aids in reducing fat but also plays a crucial role in regulating blood glucose levels.
The strategic combination of FGF-21 and IL-27 within EX105 enhances processes like lipolysis, glucose metabolism, insulin sensitivity, and glucose homeostasis, all contributing to efficient fat burning. Moreover, the ActRIIB extracellular domain counteracts the inhibitory pathways that typically suppress muscle cell growth, thereby promoting muscle mass development. By leveraging the natural properties of exosomes for transdermal delivery and intracellular transport, EX105 presents a promising avenue for localized fat reduction and muscle preservation through topical application.
In preclinical studies and human pilot data, EX105 has demonstrated its efficacy as a non-invasive topical treatment for targeted fat reduction. The application of EX105 in vivo has shown significant fat-burning effects without impacting food intake, while also increasing muscle mass proportion. Additionally, the treatment has exhibited promising metabolic benefits by reducing glucose and low-density lipoprotein levels. With its recent approval from the International Nomenclature of Cosmetic Ingredients committee, EX105 is set to enter global markets, paving the way for advanced at-home solutions for localized fat reduction.
ImmVira stands out as a global leader in clinical-stage biotechnology, specializing in oncolytic immunotherapies and engineered exosome therapies. By strategically focusing on developing innovative treatments for solid tumors and chronic diseases, the company aims to establish itself as a key player in the biotech landscape. Through a balanced product portfolio and a commitment to advancing cutting-edge therapies, ImmVira is driving forward its mission to revolutionize the field of biotechnology and improve patient outcomes worldwide.
Key Takeaways:
– ImmVira’s engineered exosome MVR-EX105 showcases a novel approach to fat reduction and muscle preservation through topical application.
– The combination of key functional proteins in EX105 triggers the conversion of white adipose tissue to brown adipose tissue, leading to fat burning and improved metabolic parameters.
– Preclinical and human pilot data support EX105’s efficacy in targeted fat reduction and muscle preservation, positioning it as a potential game-changer in the biotech industry.
– ImmVira’s dedication to advancing innovative therapies underscores its commitment to addressing unmet medical needs and driving forward the future of biotechnology.
Tags: immunotherapy, regulatory
Read more on manilatimes.net